Advertisement

Reactions Weekly

, Volume 1761, Issue 1, pp 101–101 | Cite as

Carboplatin/nivolumab/pembrolizumab

Paraneoplastic neurologic syndromes presenting as encephalitis and sensory neuronopathy: 3 case reports
Case report
  • 14 Downloads

In a case series, three patients (one man and two women) aged 58−71 years were described, who developed paraneoplastic neurologic syndromes presenting as anti-Ri brainstem encephalitis (1 patent), anti-Hu sensory neuronopathy (1 patient), and anti-Hu sensory neuronopathy and anti-N-methyl-D-aspartate (NMDA) encephalitis (1 patient) following treatment with nivolumab (1 patient) and pembrolizumab (2 patients). Addiotnally, one patient developed toxic sensory neuropathy secondary to carboplatin for metastatic lung adenocarcinoma or Merkel cell carcinoma [routes, dosages and durations of treatments to reactions onsets not stated; not all outcomes stated].

Case 1: A 71-year-old woman, who was diagnosed with stage IIa non-small cell lung cancer in 2013, had received induction chemotherapy with 4 cycles of pemetrexed, carboplatin and pembrolizumab. Further, she was maintained on pemetrexed and pembrolizumab. She presented with tremors, unsteady gait, diplopia and urinary incontinence after...

Reference

  1. Gill A, et al. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. Journal of Neuroimmunology 334: 576980, 15 Sep 2019. Available from: URL: http://doi.org/10.1016/j.jneuroim.2019.576980 - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations